PT  - JOURNAL ARTICLE
AU  - Miralles-Albors, P
AU  - Florit-Sureda, M
AU  - Perez Contel, A
AU  - Fernández-Molina, S
AU  - Barragán Muñoz, A
AU  - Gómez-Valent, M
TI  - 5PSQ-009 Evaluation of direct oral anticoagulant use in patients admitted for upper gastrointestinal and intracranial haemorrhages in the emergency service
AID  - 10.1136/ejhpharm-2020-eahpconf.326
DP  - 2020 Mar 01
TA  - European Journal of Hospital Pharmacy
PG  - A153--A154
VI  - 27
IP  - Suppl 1
4099  - http://ejhp.bmj.com/content/27/Suppl_1/A153.2.short
4100  - http://ejhp.bmj.com/content/27/Suppl_1/A153.2.full
SO  - Eur J Hosp Pharm2020 Mar 01; 27
AB  - Background and importance Upper gastrointestinal haemorrhage (UGIH) and intracranial haemorrhage (ICH) cause emergency service (ES) admissions. Glucocorticoids (GC), non-steroidal anti-inflammatory drugs (NSAID), selective serotonin reuptake inhibitors (SSRI), serotonin and norepinephrine recruitment inhibitors and platelet antiaggregants (PAA) increase the risk of UGIH and ICH when taken concomitantly with direct oral anticoagulants (DOACs). Patient age and other comorbidities (gastric lesions, liver disease, coagulopathies and hypertension) also enhance bleeding probability. In addition, some haemorrhages can be caused by a misuse of anticoagulant drugs.Aim and objectives To describe the prevalence of DOAC use in admissions for UGIH and ICH in the ES. To assess dosing and indication appropriateness of DOACs and to analyse the presence of risk factors such as concomitant drugs and comorbidities.Material and methods A Retrospective, descriptive, observational study was conducted in a university hospital. We included 14 281 patients admitted to the ES during 2018 and selected those with a diagnosis of UGIH and ICH. Data collected from patient healthcare records were age, sex, diagnosis, DOACs, renal function, drugs associated with bleeding and comorbidities.View this table:Abstract 5PSQ-009 Table 1 Conclusion and relevance The population showed a prevalence for UGIH and ICH of 1% from ES admissions, and 4.5% of these were associated with DOAC use. Only in one case was the posology inappropriate and in all patients the indication was suitable. It was observed that comorbidities may affect bleeding risk more than drugs although we should not underestimate the importance of concomitant drugs.References and/or acknowledgements No conflict of interest.